The Myoclonic Epilepsy and Ragged-Red Fiber Mutation Provides New Insights into Human Mitochondrial Function and Genetics  by Chomyn, Anne
Am. J. Hum. Genet. 62:745–751, 1998
745
MITOCHONDRIAL GENETICS ’98
The Myoclonic Epilepsy and Ragged-Red Fiber Mutation Provides New
Insights into Human Mitochondrial Function and Genetics
Anne Chomyn
Division of Biology, California Institute of Technology, Pasadena
Of the ∼50 mtDNA point mutations, reported so far,
that cause disease in humans, x35 occur in tRNA genes
(Schon et al. 1997). Of these, perhaps the best-studied
is the ArG transition at position 8344 in the tRNALys
gene, the mutation that causes myoclonic epilepsy and
ragged-red fiber syndrome (MERRF; Shoffner et al.
1990). This disorder is an encephalomyopathy charac-
terized by myoclonic epilepsy, ataxia, and mitochondrial
myopathy, with additional dysfunction, in some indi-
viduals, in tissues other than brain and skeletal muscle
(Schon et al. 1997). Histological analysis of transverse
sections of a MERRF patient’s skeletal muscle, stained
with Gomori’s modified trichrome stain, reveals the pres-
ence of “ragged red fibers,” muscle fibers that exhibit
peripheral blotchy, red patches that represent subsar-
colemmal accumulations of mitochondria.
The mammalian mitochondrial genome contains 13
reading frames, which encode subunits of respiratory-
chain enzyme complexes and the H-ATPase (Anderson
et al. 1981; Attardi et al. 1986). mtDNA also contains
genes for the large and small rRNAs and for 22 tRNAs.
The latter genes encode a complete set of tRNAs, suf-
ficient to support mitochondrial protein synthesis. Each
mitochondrial tRNA gene is essential for translation;
that is, there is no redundancy, and no tRNA appears
to be imported into mitochondria.
The 8344 tRNALys mutation, like many deleterious
tRNA mutations, occurs in a heteroplasmic state: a
MERRF patient carries both the mutant and the wild-
type alleles of the gene. The proportion of mutant DNA
varies among individuals within a MERRF maternal
lineage—and even among the tissues of the same indi-
vidual (reviewed in Shoffner and Wallace 1992; see also
Poulton 1998 [in this issue]). The relatives of the pro-
band who carry the mutation are often unaffected, or
they may exhibit only milder symptoms such as hearing
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loss or ataxia. These relatives generally have a lower
proportion of mutant mtDNA than does the proband.
Enzymological analysis of muscle-biopsy material
from MERRF patients has revealed reduced activities of
respiratory-chain enzymes (Wallace et al. 1988). Espe-
cially affected are the rotenone-sensitive NADH dehy-
drogenase, or complex I, which contains seven subunits
synthesized in mitochondria, and cytochrome c oxidase,
or complex IV, which contains three such subunits.
Any deleterious mtDNA mutation would have, as its
ultimate effect, the decreased production of ATP. In this
regard, one of the most intriguing questions regarding
MERRF—and, for that matter, other mtDNA-linked dis-
eases—concerns the mechanism by which a specific
mtDNA point mutation brings about loss of cellular
function in a tissue-specific pattern (Schon et al. 1997;
Zhou et al. 1997), so as to cause a disease different from
that caused by another mtDNA mutation. It behooves
us then to understand in depth the pathogenetic mech-
anisms associated with a particular point mutation, as
well as the biochemical consequences of different pro-
portions of mutant DNA and of its distribution among
the mitochondria of a cell. One important experimental
tool for addressing these questions, at a fundamental
level, is the use of cellular models of mitochondrial dis-
eases. Biochemical and molecular studies carried out on
the 8344 mutation and on other mtDNA mutations in
such cellular models have, over the past 7 years, revealed
surprising phenomena regarding mitochondrial biogen-
esis and genetics, and several general principles have
emerged.
Use of Transmitochondrial Cell Lines for the Analysis
of the Molecular Pathogenetic Mechanism of the
MERRF Mutation
About a year before the identification of the MERRF
8344 mutation, the first human mtDNA–less cell lines
were isolated by King and Attardi (1989). These
mtDNA-less cells, or “r0” cells (to use the designation
given to the equivalent yeast mutants), do have mito-
chondria, which maintain a membrane potential, using
the ATP/ADP translocase and glycolytically produced
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Figure 1 Relationship between rate of synthesis of the individual
mitochondrial translation products and number of lysine residues that
they contain in pT1, a transmitochondrial cybrid line that carries the
8344 mutation in nearly homoplasmic form. The protein-synthesis
data were derived from an experiment in which the mutant and control
cells were labeled with 35S-methionine for 30 min in the presence of
emetine. The labeling of the individual polypeptides in pT1 cells is
expressed as a percentage of the labeling of the same polypeptides in
pT3, a cybrid line that lacks the 8344 mutation. Rn  relative rate of
synthesis; R0  1.05; n  number of lysine residues of the individual
polypeptides. COI, COII, and COIII are subunits of cytochrome c
oxidase; ND1, ND2, ND3, ND4L, ND5, and ND6 are subunits of
NADH dehydrogenase; and A6 and A8 are subunits of the H-ATPase.
Reprinted from the study by Enriquez et al. (1995).
ATP as well as other carriers. However, lacking the 13
mtDNA-encoded polypeptides, the r0 cells do not re-
spire. r0 cells grow at an almost-normal rate in glucose-
containing culture medium supplemented with both py-
ruvate, necessary for oxidizing the cytosolic NADH via
lactate dehydrogenase (King and Attardi 1996), and uri-
dine, to compensate for the lack of pyrimidine biosyn-
thesis resulting from the absence of a functional respi-
ratory chain (Gre´goire et al. 1984).
r0 cells can be repopulated with exogenous mito-
chondria, containing wild-type mtDNA, either by pol-
yethylene glycol-mediated fusion with cytoplasts (enu-
cleated cells) or with platelets or by micro-
injection—thereby restoring pyruvate- and uridine-in-
dependent growth (see Parker and Swerdlow 1998 [in
this issue]). This provides a powerful selection for trans-
mitochondrial cybrids. Even cybrids constructed with
mitochondria carrying a deleterious mutation in their
DNA can be selected, but generally only under the less-
stringent selection conditions provided by pyruvate-sup-
plemented uridine-free medium.
When enucleated myoblasts from a MERRF patient
were fused with r0 cells, the isolated cybrid clones ex-
hibited two phenotypes: wild type, as judged by bio-
chemical and molecular criteria, and mutant, as revealed
by the extremely low levels of respiration and cyto-
chrome c oxidase activity (Chomyn et al. 1991). The
cybrids exhibiting the mutant phenotype carried the
8344 mutation in predominant form, whereas the cy-
brids displaying no phenotype carried only wild-type
mtDNA. These results provided a direct link between
the biochemical defect and the mtDNA mutation, in a
constant nuclear background. The isolation of two types
of clones derived from a single patient indicated that,
either in vivo or during culture of the myoblasts, inter-
cellular segregation of the wild-type and mutant ge-
nomes had occurred. This segregation made available,
in the convenient form of immortal cell lines, mutant
cells and their perfectly matched controls: namely, cells
with the same nuclear background, carrying the patient’s
mitochondrial genome or haplotype, but without the
MERRF mutation. This was a fortunate situation be-
cause mtDNA is highly polymorphic; the mtDNA se-
quence varies between individuals by 0.3%, on average
(Cann et al. 1987).
Effects of the 8344 Mutation on Mitochondrial
Protein Synthesis
35S-methionine pulse-labeling experiments, carried out
to investigate the effects of the mutation on mitochon-
drial protein synthesis in transmitochondrial cybrids, re-
vealed that, in addition to the 13 proteins normally syn-
thesized in mitochondria, several abnormal polypeptides
were also produced (Chomyn et al. 1991; Masucci et al.
1995). The most highly labeled one was also observed
in myoblasts and myotubes from MERRF patients (Cho-
myn et al. 1991; Boulet et al. 1992). Furthermore, the
rate of labeling of the 13 normal translation products
in the mutant cybrids was considerably decreased, a find-
ing that was not surprising, considering that the muta-
tion occurred in a tRNA gene.
A great advantage of working with the human mi-
tochondrial system is that the entire genome has been
sequenced (Anderson et al. 1981); thus, the lysine con-
tent of each polypeptide is known. Furthermore, the 13
polypeptides can be resolved electrophoretically in a
one-dimensional SDS-polyacrylamide gel, and the cor-
respondence of the polypeptides with the individual
genes is well established (Attardi et al. 1986). Thus, us-
ing the 35S-methionine pulse-labeling data from cybrids
carrying the 8344 mutation, Enriquez et al. (1995) were
able to correlate the relative synthesis rate of each poly-
peptide with the number of lysine codons in the corre-
sponding reading frame (fig. 1). The data fit an expo-
nential curve that described a model of defective protein
synthesis whereby, at each lysine codon, there was an
∼26% probability that chain elongation would termi-
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nate. Thus, polypeptides with a relatively large number
of lysine residues—such as ND2 (a subunit of the NADH
dehydrogenase), with 12 lysines—would have only a
small probability of being completed. In fact, the full-
length ND2 in the mutant cybrids was synthesized at
only ∼4% of the normal rate, which is close to the pre-
dicted 2.8% ( ). Three subunits of com-12 1.05# 0.74
plex I and one subunit of complex IV have x10 lysine
residues and were synthesized at X10% of the normal
rate in mutant cybrids, which explains the major res-
piratory and biochemical defects observed in cybrids and
in muscle biopsies of MERRF patients.
Peptide mapping and immunoprecipitation experi-
ments showed that the most highly labeled abnormal
polypeptide, pMERRF, corresponded to a truncated
form of an mtDNA-encoded subunit of cytochrome c
oxidase, COI, and several other proteins were identified
as N-terminal fragments of ND2 (Enriquez et al. 1995).
Thus, the abnormal polypeptides appeared indeed to be
products of premature termination of translation.
How Is the tRNALys Affected by the Mutation?
The 8344 mutation occurs in the tRNALys loop equiv-
alent of the universal TWC loop. An effect of the mu-
tation on the accuracy of processing of the polycistronic
transcript from which the tRNALys is derived was ruled
out by the results of RNA gel-blot analysis. Both the
mature mRNAs corresponding to the adjacent genes and
the mature tRNALys were of the correct size in the mutant
cybrids (Enriquez et al. 1995). However, the same type
of analysis revealed that the steady-state level of the mu-
tant tRNALys was decreased by 18%–35%. Furthermore,
using conditions of isolation and electrophoresis that
protected the amino acid–tRNA bond, Enriquez et al.
(1995) found that the proportion of tRNALys that was
charged was decreased in the mutant cells by 30%–40%.
The combination of the two factors (amount and ami-
noacylation efficiency) produced a level of lysyl-tRNALys
that was 50%–60% lower in mutant cells than in control
cells.
Did the mutant charged tRNALys have any elongator
activity? The mtDNA in the mutant cybrid cell line used
most extensively in the work by Enriquez et al. (1995),
pT1, had x98% mutant mtDNA; furthermore, only
mutant tRNALys could be detected in pT1 cells. Yet the
cells were able to translate, albeit at a low rate, most
mitochondrial mRNAs. In the case of the polypeptide
least affected in its rate of synthesis, ND6, which has
only two lysine residues, the rate of formation of the
finished protein was reduced in pT1 cells by only 40%,
relative to the control cell line (fig. 1). It is unlikely that
the vanishingly small amount of wild-type tRNALys gene
possibly present in pT1 cells could account for the pro-
tein synthesis observed in these cells. Indeed, pT1 cells
were able to incorporate 3H-lysine into all the various
mitochondrial translation products except ND4L, which
has no lysine codon in its reading frame. When com-
pared to the labeling pattern of a control cybrid, the
polypeptides most affected in their labeling rates by the
mutation were the same as those showing the most dif-
ferences after 35S-methionine labeling (Enriquez et al.
1995). Not only did these results indicate the substantial
functionality of the mutant tRNA in elongation, but they
also ruled out any significant misincorporation of lysine
residues or incorporation of other amino acids at lysine
codons. The latter finding is in agreement with the lack
of evidence of misacylated tRNALys in electrophoretic
analysis of tRNALys charged in vivo.
It is likely that the decrease in the level of charged
tRNALys in cells with the 8344 mutation can completely
account for the observed premature termination of
translation. This premature termination may be due to
ribosomal frameshifting or to premature release of pep-
tidyl-tRNA. Unfortunately, there is limited information,
from other systems, on premature termination of trans-
lation resulting from reduced levels of charged tRNA.
In bacteria, protein synthesis rates decrease rapidly when
the ratio of charged tRNA to uncharged tRNA drops
below a certain level, and the possibility has been raised
that uncharged tRNA binding to the A site might lead
to premature termination of translation (Goldman and
Jakubowski 1990).
Like the MERRF mutation at position 8344, a mu-
tation at position 8356 in the tRNALys gene causes trans-
mitochondrial cell lines to produce an abnormal trans-
lation product of the size of pMERRF (Masucci et al.
1995). Apart from these two tRNALys mutations, no
other mitochondrial tRNA mutation has been observed
to cause premature termination of translation. Lympho-
blastoid cell lines carrying a deafness-associated mtDNA
mutation at position 7445 (Reid et al. 1994) process the
tRNASerUCN inefficiently, and the steady-state level of this
tRNA is consequently diminished by 60%–75% (Guan
et al. 1997; Reid et al. 1997). The absence of any trun-
cated polypeptides in these cells and the results of anal-
ysis of the translation rates of various UCN-containing
mRNAs suggest that the tRNASerUCN causes a transient
pause, rather than premature termination, in translation
(M.-X. Guan, J. A. Enriquez, and G. Attardi, personal
communication). The mutation at position 3243 in the
tRNALeuUUR gene, which is associated with mitochondrial
encephalomyopathy, lactic acidosis, and stroke-like ep-
isodes (MELAS) or with non–insulin-dependent diabetes
mellitus (NIDDM; see Schon et al. 1997), causes a sim-
ilar decrease (∼65%) in the level of leucyl-tRNALeuUUR,
but, again, no correlation has been found between the
decrease in the synthesis rate of a given polypeptide and
the number of UUR codons in its reading frame, nor has
any truncated polypeptide been observed (Chomyn et
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Figure 2 A small minority of wild-type mtDNA can correct the
defective respiration caused by the 8344 MERRF mutation in different
heteroplasmic transformants. Each type of symbol represents a dif-
ferent transmitochondrial clone. Individual clones were sampled over
an extended period of time during which the genotype of some of the
clones drifted toward a higher proportion of mutant DNA. Modified
from the study by Yoneda et al. (1994).
al. 1997). Thus, in the human mitochondrial system,
lysine codons appear to be unique in their ability to cause
premature termination of translation when the supply
of charged tRNA is low.
Is There Normally an Excess of Mitochondrial tRNA?
Is the normal level of mitochondrial tRNAs in cells
in culture rate limiting for protein synthesis, or is it in
excess and, if so, how much? These questions are dif-
ficult to address in the organism, but it is possible to
make an estimate of the amount of functional mito-
chondrial tRNA required to support protein synthesis
in human cells in culture.
Hayashi et al. (1991) constructed a series of hetero-
plasmic transmitochondrial cell lines carrying both wild-
type mtDNA and, in varying proportions, the mutant
mtDNA that is associated with chronic progressive ex-
ternal ophthalmoplegia. The latter DNA contains a 5-
kb deletion that eliminates three reading frames and five
tRNA genes, and it creates a fusion reading frame con-
taining ATPase 6 and ND5 sequences. In a mitochon-
drion containing only mutant genomes, no protein syn-
thesis would occur, because of the lack of five tRNA
genes. On the contrary, Hayashi et al. (1991) found that
the fusion reading frame was translated in cells in which
X55% of their mitochondrial genomes carried a dele-
tion. This complementation indicated that the products
of the wild-type mitochondrial genomes mixed with the
products of the deletion genomes. Hayashi et al. (1991)
also observed a dramatic effect of varying the proportion
of wild-type and mutant mtDNAs on the rate of syn-
thesis of proteins encoded by the nondeleted genes.
When x45% of the mitochondrial genomes were wild
type, synthesis of cytochrome c oxidase subunit II pro-
ceeded at the wild-type rate. With lower proportions of
wild-type mtDNA, the synthesis rate declined sharply.
Thus, assuming that the amount of a given wild-type
tRNA is proportional to the number of genes for that
tRNA, normal protein-synthesis rates required that one
or more of the five tRNAs be expressed at a level x45%
of the wild-type level.
In a study using transmitochondrial cybrids that car-
ried different proportions of wild-type and MERRF
mtDNA, Yoneda et al. (1994) found that respiration
rates were normal if x10% of the mitochondrial ge-
nomes were wild type (fig. 2). This result agreed with
the findings of an earlier study in which cultured my-
otubes heteroplasmic for the 8344 mutation showed an
∼15% threshold for cytochrome c oxidase activity and
cytochrome c oxidase subunit I synthesis (Boulet et al.
1992). Moreover, these results were fully consistent with
data from muscle biopsies from MERRF families, which
showed that the mutant DNA had to be present in high
proportion, 185%, before clinical symptoms appeared
(Shoffner and Wallace 1992). These thresholds for the
8344 MERRF mutation seemed to be at odds with the
finding of Hayashi et al. (1991) that x45% of the ge-
nomes in cells heteroplasmic for the large deletion must
be wild type for full complementation to occur. However,
this apparent discrepancy simply reflects the leakiness of
the tRNALys mutation in MERRF cells, where tRNALys
is inefficiently charged but, once charged, participates
normally in protein synthesis.
According to this interpretation, the primary basis for
the decreased protein-synthesis rate in homoplasmic or
nearly homoplasmic MERRF mutant cells is the shortage
of charged tRNALys molecules (or the lower ratio of
charged to uncharged tRNALys). In heteroplasmic cells,
complementation occurs when enough wild-type lysyl-
tRNALys is present to bring the level of total charged
tRNALys up to the minimum level (or to the correct ratio
of charged to uncharged tRNA) required to support nor-
mal protein-synthesis rates. In the investigations of the
MERRF mutation described above, the level of charged
tRNALys in the nearly homoplasmic mutant cybrid cell
lines was 40%–50% of the control level. The capacity
of 10% wild-type genomes to restore in the cells a nor-
mal rate of mitochondrial protein synthesis would imply
that, under the assumption of an intrinsically normal
elongator activity of the mutant tRNALys, the threshold
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for the amount of lysyl-tRNALys required for normal
translation is ∼50% of the control level—that is, very
close to the threshold for a wild-type tRNA gene level
determined by the data of Hayashi et al. (1991).
With regard to other mitochondrial tRNAs, the mu-
tation at position 7445, which was mentioned above,
revealed a threshold for the tRNASerUCN of ∼40% as be-
ing required to support a normal rate of protein synthesis
(M.-X. Guan, J. A. Enriquez, and G. Attardi, personal
communication). Therefore, it appears from the avail-
able data that the mitochondrial tRNALys, the mito-
chondrial tRNASerUCN, and at least one other mitochon-
drial tRNA are normally present in cultured human cells
in amounts not much in excess over what is needed in
the cell. Further work is necessary to establish whether
this conclusion can be extended to most, if not all, mi-
tochondrial tRNAs, as seems reasonable.
Can mtDNA with the MERRF Mutation Complement
Other Mutant Genomes?
A minority (10%) of wild-type genomes in transmi-
tochondrial cybrids containing the 8344 MERRF mu-
tation or the 3243 MELAS/NIDDM mutation in the
tRNALeuUUR gene is sufficient to complement the mutant
genomes and to support a normal respiration rate
(Yoneda et al. 1994). In this reflected mitochondrial fu-
sion, one would expect that, when cytoplasts containing
virtually only mutant mtDNA in the tRNALys gene were
fused with cybrids carrying predominantly mutant
mtDNA in the tRNALeuUUR gene, full protein-synthetic
capacity and respiration would be restored. However,
when Yoneda et al. (1994) carried out such a fusion, of
116 clones isolated without selection for respiration, 5
were found to contain x12% of each type of mtDNA,
but none of them exhibited any complementation. All
five clones had markedly low respiration rates and low
protein-synthesis rates. These results were interpreted as
indicating that the products of the MERRF and the ME-
LAS genomes did not mix, so as to allow complemen-
tation to occur, and that the genomes were compart-
mentalized, perhaps within autonomous mitochondria.
A reasonable explanation of why complementation
occurred between the mutant and wild-type genomes in
cells derived from the same individual in the threshold
experiments described earlier, is that the mutant genome
originally arose among the wild-type genomes within
one mitochondrion. Thereafter, this mutant genome was
maintained with wild-type genomes within the same mi-
tochondrial compartments during growth and division,
for the obvious selective advantage that intramitochon-
drial complementation would provide.
The number of clones analyzed in the work of Yoneda
et al. (1994) was small, and it was quite possible that,
if selection for respiration had been applied on a large
population of newly constructed cybrids, some clones
with complementing genomes would have been isolated.
Takai et al. (1997), applying very stringent selection con-
ditions, were able to isolate cybrids in which comple-
mentation of two mtDNA mutations had occurred.
More recently, J. Cabezas-Herrera, J. A. Enriquez, and
G. Attardi (personal communication) have applied se-
lection to a large-scale r0 # cytoplast fusion that was
made between cells carrying the 8344 MERRF mutation
in 199% of their genomes and cells carrying a homo-
plasmic frameshift mutation in the ND4 gene. Very few
cells survived the selection. These survivors, clones that
carried both mitochondrial genomes and in which com-
plementation between them had presumably occurred,
represented only a very small fraction (!1%) of the total
number of cybrids formed. These were quantified by
screening clones from the same fusion mixture for the
simultaneous presence of the two mtDNAs. These re-
sults, therefore, clearly confirmed the earlier finding that
mixing of mitochondrial genomes originating in distinct
organelles is infrequent, at least in established cell lines.
Mitochondrial fusion is, however, well documented in
certain developmental situations—namely, in gameto-
genesis (Hales and Fuller 1997) and in muscle devel-
opment (Bakeeva et al. 1981; Boulet et al. 1992).
Future research will be aimed at understanding the
behavior of the mitochondria and their DNA during
growth and cell division and in postmitotic cells, and
the factors that control mitochondrial fusion and
mtDNA complementation and segregation. This under-
standing may someday provide the basis for therapies
aimed at restoring the predominance of wild-type
mtDNA in a heteroplasmic cell. Furthermore, we may
learn the basis for the occurrence of distinct diseases
produced by different mutations and for the variety of
clinical phenotypes produced by the same mutation. Of
course, the site of the mutation is important. Even mu-
tations in tRNA genes will affect the four oxidative phos-
phorylation complexes containing mtDNA-encoded
subunits differently (see fig. 1, for example). This bias
in affected complexes was explicitly demonstrated by
Villani and Attardi (1997) for cells bearing the 8344
MERRF mutation. Aside from this very fundamental
aspect, the factors that are important for producing a
particular phenotype may include the extent of leakiness
of a given mutation, whether the mutation is recessive
or dominant in a heteroplasmic situation, whether it can
be complemented by wild-type mtDNA in the same or-
ganelle, and, if the mutation can be complemented, what
the threshold of complementation of mutant mtDNA by
wild-type genomes is. Also of major importance are the
distribution of the mitochondrial genotypes among the
mitochondria and the capacity of mitochondrial ge-
nomes carried within distinct organelles to interact with
each other.
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Superimposed on these phenomena would be growth
control of the cells and cellular energy needs. In a pro-
liferating tissue, such as lymphocytes, segregation of the
mutation may lead to selection against cells having more
homoplasmic mutant mitochondria. This segregation
could account for the finding that lymphocytes often
have lower proportions of mutant mtDNA than does
muscle (Shoffner and Wallace 1992). Also, the role of
segregation of wild-type and mutant mitochondrial ge-
nomes, during development, in generating a specific phe-
notype is of key importance and has been discussed
(Schon et al. 1997). Nuclear factors clearly play a role
in many of the factors mentioned above. Finally, because
mitochondrial gene products interact directly with nu-
clear gene products to form enzyme complexes, an in-
dividual’s nuclear makeup could also influence the se-
verity of the disease phenotype. Not all of the above
questions can be addressed by the use of cells in culture,
but, certainly, cellular models of mitochondrial diseases
isolated by repopulation of mtDNA-less cells, by im-
mortalization of patients’ cells, or by myoblast fusion,
will continue to play an important role in these
investigations.
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